TransCode gets Nasdaq extension to regain compliance; Public Reprimand issued

Transcode Therapeutics, Inc.

Nasdaq Hearings Panel granted extension to comply with Bid Price Rule 5550(a)(2), Equity Rule 5550(b), and Shareholder Approval Rule 5635(d).
Company issued 10M shares at $0.30 on July 22, 2024, a 62% discount to the $0.7925 minimum price, without shareholder approval.
Panel issued a Public Reprimand Letter for the unauthorized issuance; company remains listed subject to conditions.
TransCode must demonstrate compliance with listing rules within the extension period or face delisting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.